The Esophageal Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Esophageal Cancer: An Overview
Esophageal cancer is a male-dominant aggressive malignancy and a leading cause of cancer-related mortality worldwide. Squamous cell carcinoma and adenocarcinoma are the two predominant histological subtypes with the varying geographical and racial distribution.
Esophageal cancer continues to be a predominantly fatal disease with only modest improvements in survival over the last three decades. Squamous cell cancer continues to be the most common histological subtype globally and accounts for most deaths from esophageal cancer. In the Western world, the incidence of esophageal adenocarcinoma has superseded that of esophageal squamous cell carcinoma, with most cases occurring in Caucasian males.
Esophageal Cancer Market Key Facts
-
According to the National Organization for Rare Disorders: Approximately 17,000 people are diagnosed with esophageal cancer in the United States each year. Squamous cell carcinoma and adenocarcinoma account for about 95% of people with esophageal cancer.
-
According to Mark Krasana et.al., Esophageal cancer continues to be a largely fatal malignancy, with overall five-year survival ranging from 15% to 20%. In the USA, the incidence of EAC among white men was 0.4 per 100,000 in 1973 to 2.8 per 100,000 in 2012.
-
According to Globocan, esophageal cancer is the tenth most common malignancy and the seventh most common cause of cancer death in Japan, with an estimated 17 497 new cases and 11 746 deaths in 2008.
-
Esophageal cancer is more common among men than among women. The lifetime risk of esophageal cancer in the United States is about 1 in 125 in men and about 1 in 417 in women.
Esophageal Cancer market size is anticipated to increase during the study period owing to the rise in the number of Incident cases in 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Esophageal Cancer market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Esophageal Cancer market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Get the PDF Sample of the Report:- Esophageal Cancer Therapeutics Market
Esophageal Cancer Epidemiology
The epidemiology section covers insights about the historical and current Esophageal Cancer patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Esophageal Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Esophageal Cancer market or expected to get launched in the market during the study period. The analysis covers Esophageal Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Esophageal Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Esophageal Cancer Therapeutics Analysis
The pipeline of Esophageal Cancer is quite robust with several products available in the developmental stage. At present several key players are involved in the development of promising products.
The dynamics of the Esophageal Cancer market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world. The launch of several emerging therapies is expected during the forecast period of 2021-2030.
Some of the key Companies in the Esophageal Cancer Market Includes:
-
Apexigen
-
Takeda
-
Shanghai Junshi
-
Jiangsu Hengrui Medicine
-
Sunshine Lake Pharma
-
Innovent Biosciences
-
Lee Pharmaceutical
And many others
Esophageal Cancer Therapies covered in the report include:
-
Toripalimab
-
SHR-1210
-
Larotinib
-
IBI308
-
ZKAB 001
-
Simurosertib
And many more
Get More Detailed Insights into the Emerging Therapies & Key Companies:- Chronic Insomnia Therapeutics Landscape
Table of Content
1. Key Insights
2. Executive Summary
3. Esophageal Cancer Competitive Intelligence Analysis
4. Esophageal Cancer Market Overview at a Glance
5. Esophageal Cancer Disease Background and Overview
6. Esophageal Cancer Patient Journey
7. Esophageal Cancer Epidemiology and Patient Population
8. Esophageal Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Esophageal Cancer Unmet Needs
10. Key Endpoints of Esophageal Cancer Treatment
11. Esophageal Cancer Marketed Products
12. Esophageal Cancer Emerging Therapies
13. Esophageal Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Esophageal Cancer Market Outlook (7 major markets)
16. Esophageal Cancer Access and Reimbursement Overview
17. KOL Views on the Esophageal Cancer Market.
18. Esophageal Cancer Market Drivers
19. Esophageal Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/esophageal-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/